Immuno engineering biomaterials for stem-cell-derived beta cell transplantation in type 1 diabetes

In their PhD project they aim to engineer a biomaterial, which can deliver stem-cell-derived beta cells encased in biomimetic materials which are further functionalised with IL-35 to prevent immune attack. Once the biomaterial has been effectively functionalised, we can investigate the viability and function of stem cell

derived beta cells. Moving onto preclinical assessments, the biomaterial and cell therapy will be tested in

diabetic mouse models. I hypothesise that IL-35 engineered biomaterials will significantly enhance the success rate of stem-cell derived beta cell transplantation. Specifically, I anticipate that it will foster immune tolerance, prolong graft survival, result in sustained insulin production, improve overall glycaemic control in T1D models, and

provide proof on concept for human translation. This research study will provide invaluable interdisciplinary training in bioengineering for regenerative medicine and an unparalleled opportunity to propel my future career in academia. I will develop an expertise in immuno-engineering and protein engineering applications (synthesising cytokines and

functionalising biomaterials). I will cultivate a proficiency in managing and studying preclinical T1D models, encompassing skills such as monitoring glycaemic control, evaluating transplantation outcomes in animal models. I will navigate first-hand the challenges of diabetes and auto-immune diseases research, creating

a personalising approach to treatment and understanding the individual patient's needs thanks to the clinical specialists. Finally, the active engagement with experts in stem cell biology, immunology, biomaterial engineering and the co-supervision of Dr Ishihara and Dr Salem would help me develop a collaborative mindset.